Sumitomo Mitsui Trust Group Inc. Has $781.11 Million Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Sumitomo Mitsui Trust Group Inc. reduced its stake in Intuitive Surgical by 1.5%, owning 1,437,418 shares valued at approximately $781 million as of the latest SEC filing.
• Insider Gary S. Guthart sold 29,360 shares of Intuitive Surgical for over $13 million, decreasing his position by nearly 60%.
• Intuitive Surgical's recent earnings report showed a 22.9% increase in revenue year-over-year, with an earnings per share (EPS) of $2.40, surpassing analysts' expectations.

Sumitomo Mitsui Trust Group Inc. cut its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,437,418 shares of the medical equipment provider's stock after selling 22,087 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.40% of Intuitive Surgical worth $781,107,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Ground Swell Capital LLC acquired a new position in shares of Intuitive Surgical during the second quarter valued at $453,000. Blue Sky Capital Consultants Group Inc. raised its position in Intuitive Surgical by 35.2% in the 2nd quarter. Blue Sky Capital Consultants Group Inc. now owns 7,713 shares of the medical equipment provider's stock valued at $4,191,000 after buying an additional 2,009 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in Intuitive Surgical by 8,900.0% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 180 shares of the medical equipment provider's stock valued at $98,000 after buying an additional 178 shares during the last quarter. Asset Management One Co. Ltd. raised its position in Intuitive Surgical by 0.8% in the 2nd quarter. Asset Management One Co. Ltd. now owns 193,600 shares of the medical equipment provider's stock valued at $105,204,000 after buying an additional 1,602 shares during the last quarter. Finally, R Squared Ltd grew its stake in Intuitive Surgical by 267.5% in the second quarter. R Squared Ltd now owns 2,793 shares of the medical equipment provider's stock valued at $1,518,000 after purchasing an additional 2,033 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Insider Buying and Selling

In other news, insider Gary S. Guthart sold 29,360 shares of the business's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $472.49, for a total value of $13,872,306.40. Following the sale, the insider directly owned 19,827 shares of the company's stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Amy L. Ladd sold 335 shares of the business's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $440.69, for a total transaction of $147,631.15. Following the completion of the transaction, the director owned 739 shares of the company's stock, valued at approximately $325,669.91. The trade was a 31.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,724 shares of company stock worth $19,500,332. Insiders own 0.70% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ISRG shares. Jefferies Financial Group lifted their price target on Intuitive Surgical from $550.00 to $560.00 and gave the stock a "hold" rating in a report on Wednesday. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. HSBC upped their target price on Intuitive Surgical from $595.00 to $644.00 and gave the company a "buy" rating in a research report on Thursday. Royal Bank Of Canada set a $625.00 target price on Intuitive Surgical and gave the company an "outperform" rating in a research report on Wednesday. Finally, Daiwa Capital Markets upped their price target on Intuitive Surgical from $510.00 to $550.00 and gave the stock an "outperform" rating in a research note on Friday. Nineteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Intuitive Surgical currently has an average rating of "Moderate Buy" and a consensus target price of $602.32.

Intuitive Surgical Stock Down 0.6%

NASDAQ ISRG opened at $547.89 on Friday. The company has a market capitalization of $196.41 billion, a price-to-earnings ratio of 72.47, a PEG ratio of 5.53 and a beta of 1.61. The stock's 50-day simple moving average is $456.77 and its two-hundred day simple moving average is $496.40. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.41. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.41 billion. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.Intuitive Surgical's revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.84 EPS. On average, equities analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.